The Osteoclast in Bone Metastasis: Player and Target

Therapeutic approaches for protecting bone health in patients with breast cancer

(2018) Diana Lüftner et al.   BREAST

The bone remodelling cycle

(2018) JS Kenkre et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Calcium-Sensing Receptor Promotes Breast Cancer by Stimulating Intracrine Actions of Parathyroid Hormone–Related Protein

(2016) Wonnam Kim et al.   CANCER RESEARCH

Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement

(2016) Jawed A. Siddiqui et al.   PHYSIOLOGY

Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review

(2016) Pui Kit Suen et al.   Journal of Orthopaedic Translation

Hypocalcaemia in patients with metastatic bone disease treated with denosumab

(2015) Jean-Jacques Body et al.   EUROPEAN JOURNAL OF CANCER

A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

(2015) Robert R. Recker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Risks and Benefits of Bisphosphonate Therapies

(2015) Carlen Reyes et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Tumour but not stromal expression ofβ3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer

(2015) Rachel Zoe Carter et al.   JOURNAL OF PATHOLOGY

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

(2015)   LANCET

Reprint of: The Great Beauty of the osteoclast

(2014) Alfredo Cappariello et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

RANK expression as a prognostic and predictive marker in breast cancer

(2014) Berit Maria Pfitzner et al.   BREAST CANCER RESEARCH AND TREATMENT

Integrating new discoveries into the “vicious cycle” paradigm of prostate to bone metastases

(2014) Leah M. Cook et al.   CANCER AND METASTASIS REVIEWS

Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer

(2014) Ioannis Kyvernitakis et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osteolytic bone metastasis is hampered by impinging on the interplay among autophagy, anoikis and ossification

(2014) P Maroni et al.   Cell Death & Disease

Podosomes in adhesion, migration, mechanosensing and matrix remodeling

(2013) Hannah Schachtner et al.   Cytoskeleton

WNT signaling in bone homeostasis and disease: from human mutations to treatments

(2013) Roland Baron et al.   NATURE MEDICINE

The role of estrogen and androgen receptors in bone health and disease

(2013) Stavros C. Manolagas et al.   Nature Reviews Endocrinology

Osteopetrosis: genetics, treatment and new insights into osteoclast function

(2013) Cristina Sobacchi et al.   Nature Reviews Endocrinology

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

(2012) R. Coleman et al.   ANNALS OF ONCOLOGY

New regulation mechanisms of osteoclast differentiation

(2012) Tomoki Nakashima et al.   Annals of the New York Academy of Sciences

Treatment of bone metastases before the onset of pain

(2012) Luis Costa et al.   International Journal of Clinical Oncology

Biochemical and molecular mechanisms of action of bisphosphonates

(2010) Michael J. Rogers et al.   BONE

Pathogenesis of osteoblastic bone metastases from prostate cancer

(2010) Toni Ibrahim et al.   CANCER

The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial

(2010) Anders Bonde Jensen et al.   Clinical Breast Cancer

Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?

(2010) Izabela Podgorski   Future Medicinal Chemistry

Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women

(2010) Rowan T. Chlebowski et al.   JOURNAL OF CLINICAL ONCOLOGY

SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis

(2010) S. A. Rabbani et al.   MOLECULAR CANCER THERAPEUTICS

Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model

(2010) J. C. Yang et al.   MOLECULAR CANCER THERAPEUTICS

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

(2010) Eva Gonzalez-Suarez et al.   NATURE

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

(2010) Daniel Schramek et al.   NATURE

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

(2010) Y-C Lee et al.   ONCOGENE

Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesisviathe HIF-1α/VEGF signaling pathways in human breast cancer cells

(2009) Xudong Tang et al.   INTERNATIONAL JOURNAL OF CANCER

The Women's Health Initiative: Lessons Learned

(2008) Ross L. Prentice et al.   Annual Review of Public Health

Osteoclast receptors and signaling

(2008) Andrea Del Fattore et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Infantile Malignant, Autosomal Recessive Osteopetrosis: The Rich and The Poor

(2008) Anna Villa et al.   CALCIFIED TISSUE INTERNATIONAL

Osteoclast Precursor Interaction with Bone Matrix Induces Osteoclast Formation Directly by an Interleukin-1-mediated Autocrine Mechanism

(2008) Zhenqiang Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines

(2008) Anders Ullén et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY